Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease

Soursou, Georgia; Alexiou, Athanasios; Ashraf, Ghulam Md; Siyal, Asad Ali; Mushtaq, Gohar; Kamal, Mohammad Amjad

doi:10.2174/138920021608151107125049

Cited by 21 publications

(10 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of late, AD has been found to coexist with other chronic diseases like cancer, diabetes, and cardiovascular diseases (Aliev et al, 2014 ; Jabir et al, 2015 ; Rizvi et al, 2015 ; Ashraf et al, 2016 ). This has opened up new dimensions of AD diagnosis and therapy based on proteomics (Ashraf et al, 2014 , 2015 ) and nanotechnology (Soursou et al, 2015 ; Ansari et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Sleep Disorders Associated With Alzheimer's Disease: A Perspective

et al. 2018

View full text Add to dashboard Cite

Sleep disturbances, as well as sleep-wake rhythm disturbances, are typical symptoms of Alzheimer's disease (AD) that may precede the other clinical signs of this neurodegenerative disease. Here, we describe clinical features of sleep disorders in AD and the relation between sleep disorders and both cognitive impairment and poor prognosis of the disease. There are difficulties of the diagnosis of sleep disorders based on sleep questionnaires, polysomnography or actigraphy in the AD patients. Typical disturbances of the neurophysiological sleep architecture in the course of the AD include deep sleep and paradoxical sleep deprivation. Among sleep disorders occurring in patients with AD, the most frequent disorders are sleep breathing disorders and restless legs syndrome. Sleep disorders may influence circadian fluctuations of the concentrations of amyloid-β in the interstitial brain fluid and in the cerebrovascular fluid related to the glymphatic brain system and production of the amyloid-β. There is accumulating evidence suggesting that disordered sleep contributes to cognitive decline and the development of AD pathology. In this mini-review, we highlight and discuss the association between sleep disorders and AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Sleep Disorders Associated With Alzheimer's Disease: A Perspective

et al. 2018

View full text Add to dashboard Cite

show abstract

“…While several attempts at reducing AD severity have already been presented targeting mainly the symptomatic treatment (Ashraf et al, 2015) until now, there is no holistic therapy available that can efficiently reverse AD. For many scientists and pharmaceuticals companies, there are several and different treatment approaches for AD such as cholinesterase inhibitors, NMDA receptor antagonist, β-secretase inhibitors, γ-secretase inhibitors, α-secretase stimulators, tau inhibitors, immunotherapy, nutraceuticals, and nano drugs (Ashraf et al, 2015; Soursou et al, 2015) even though the more secure solution seems to be the early diagnosis of neurodegeneration signs, in order to facilitate the early diagnosis or prediction.…”

Section: Introductionmentioning

confidence: 99%

A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease

Alexiou¹,

Mantzavinos

Greig

et al. 2017

Front. Aging Neurosci.

Self Cite

View full text Add to dashboard Cite

Alzheimer's disease treatment is still an open problem. The diversity of symptoms, the alterations in common pathophysiology, the existence of asymptomatic cases, the different types of sporadic and familial Alzheimer's and their relevance with other types of dementia and comorbidities, have already created a myth-fear against the leading disease of the twenty first century. Many failed latest clinical trials and novel medications have revealed the early diagnosis as the most critical treatment solution, even though scientists tested the amyloid hypothesis and few related drugs. Unfortunately, latest studies have indicated that the disease begins at the very young ages thus making it difficult to determine the right time of proper treatment. By taking into consideration all these multivariate aspects and unreliable factors against an appropriate treatment, we focused our research on a non-classic statistical evaluation of the most known and accepted Alzheimer's biomarkers. Therefore, in this paper, the code and few experimental results of a computational Bayesian tool have being reported, dedicated to the correlation and assessment of several Alzheimer's biomarkers to export a probabilistic medical prognostic process. This new statistical software is executable in the Bayesian software Winbugs, based on the latest Alzheimer's classification and the formulation of the known relative probabilities of the various biomarkers, correlated with Alzheimer's progression, through a set of discrete distributions. A user-friendly web page has been implemented for the supporting of medical doctors and researchers, to upload Alzheimer's tests and receive statistics on the occurrence of Alzheimer's disease development or presence, due to abnormal testing in one or more biomarkers.

show abstract

“…Nanotechnology has been used for both diagnosis and therapeutics of the PD in advance medical studies worldwide [14][15][16]. For PD diagnosis, several nanobiosensors have been developed so far based on the quantification of different biomarkers of PD such as dopamine [17,18], alpha-synuclein protein [19], homovanilic acid [20] and even PD-related genetic mutation [21].…”

Section: Introductionmentioning

confidence: 99%

A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s disease

Aghili

Nasirizadeh

Divsalar

et al. 2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Early detection of Parkinson's disease (PD), as a dangerous neurodegenerative disease, is a key factor in the therapy or prevention of further development of this disease. We developed an electrochemical nanobiosensor for early detection of PD based on the quantification of circulating biomarker, miR-195. Exfoliated graphene oxide (EGO) and gold nanowires (GNWs) were used to modify the surface of screen-printed carbon electrode. A single-strand thiolated probe was designed for specific hybridization with target miRNA (miR-195), and doxorubicin was used as an electrochemical indicator for differential pulse voltammetry measurements. The results of scanning electron microscope imaging and cyclic voltammetry experiments confirmed the accuracy of the working electrode modification steps. The results of analytical performance nanobiosensor showed a high sensitivity of the biosensing with 2.9 femtomolar detection limit and dynamic range of 10.0-900.0 femtomolar. In addition, good selectivity for target miRNA over non-specific oligonucleotides (one and three base replacement in target miRNA, and non-complementary) was achieved. The results of real human serum analysis did not show any interference in the function of the biosensor. Based on the results, the miR-195 electrochemical nanobiosensor could be suggested for clinicians in the medical diagnosis of PD.

show abstract

Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease

Cited by 21 publications

References 69 publications

Sleep Disorders Associated With Alzheimer's Disease: A Perspective

Sleep Disorders Associated With Alzheimer's Disease: A Perspective

A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease

A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s disease

Contact Info

Product

Resources

About